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Objectives: This study aimed to adapt the ADPKD Outcomes Model in order to 
compare the Chronic Kidney Disease progression and relative costs of Autosomal 
Dominant Polycystic Kidney Disease (ADPKD)-affected patients treated with JINARC 
as compared to non-treated patients in Italy. MethOds: Utilising the structure 
of the ADPKD Outcomes Model adapted to the Italian context, the analysis has 
simulated the evolution of ADPKD patients over a period of 80 years. The study 
was performed from both the National Health Service and social perspectives. The 
ADPKD Outcomes Model is based on a series of annual simulations at the individual 
patient level that allows clinical evolutions, such as the achievement of end-stage 
renal disease (ESRD). The model is able to incorporate country-specific pathways for 
ESRD-affected patients, such as haemodialysis (HD), peritoneal dialysis (PD), trans-
plant and conservative therapy, together with their different costs and mortality 
rates. Clinical data on treatment effect of tolvaptan were derived from TEMPO 3:4 
clinical trial. Results: The results show that tolvaptan is estimated to postpone the 
time-to-ESRD by a mean of around 3.7 years and increase life expectancy by a mean 
of 1.6 years. It is predicted that a larger number of ESRD events and deaths could 
be avoided among treated patients vs non-treated patients (e.g. 346 ESRD events 
avoided, and 68 deaths for ESRD avoided at 15 years). In addition, the cumulative cost 
per patient treated who reaches ESRD, compared to non-treated patient, generates 
overall savings in the medium to long-term (e.g. at 15 years, € 16.6 million saved for 
HD and € 2.0 million saved for PD). cOnclusiOns: The use of JINARC in ADPKD 
patients permits not only a slowing down in the worsening of the disease, but also 
an increase in life expectancy and the achievement of a considerable decrease in 
direct and indirect health costs in the medium to long-term.
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Objectives: To assess the cost-effectiveness of delayed-release dimethyl fuma-
rate (DMF) versus treatments for relapsing remitting multiple sclerosis (RRMS) 
from a Spanish Health System perspective. MethOds: A decision analytic 
Markov model was developed to assess the cost-effectiveness of DMF versus IFN 
beta (IFNβ )-1a IM, IFNβ -1a 22 and 44 mcg SC, IFNβ -1b SC, glatiramer acetate (GA) 
SC, teriflunomide, fingolimod and natalizumab in RRMS patients. Based on the 
Expanded Disability Status Scale (EDSS), 21 health states were defined (EDSS 0-9 
RRMS, EDSS 0-9 SPMS and death). Disability disease progression rate, relapse rate, 
treatment disutility, adverse events, rates of withdrawal and disease related mor-
tality were assessed over a 30-year period. Data sources included published litera-
ture, clinical trials, Spanish price/tariff lists, and national population statistics. 
Results are presented as quality-adjusted life-years (QALY) and incremental cost 
effectiveness ratio (ICER). Univariate and probabilistic sensitivity analyses were 
performed. Results: DMF showed higher QALYs and lower costs compared to 
IFNβ -1a IM (0.122 QALYs; -2,761€ ), IFNβ -1a 44mcg SC (0.093 QALYs; -8,827€ ), IFNβ -1b 
SC (0.286 QALYs; -7,108€ ), GA SC (0.235 QALYs; -1,040€ ), teriflunomide (0.125 QALYs; 
-260€ ) and fingolimod (0.184 QALYs; -29,813€ ). In the comparison of DMF vs IFNβ -1a 
22 mcg SC, DMF provided incremental QALYs of 0.193 and an anticipated ICER of 
23,482€ . Compared to natalizumab, DMF showed incremental QALYs of -0.143 and 
incremental costs of -29.001€ , being less effective and cheaper. Sensitivity analyses 
demonstrated the robustness of the model. At a decision-maker’s willingness to 
pay of < 30.000€ , DMF was cost-effective in more than 80% of simulations versus 
IFN beta-1a IM, IFNβ -1a 44 mcg SC, IFNIβ -1b SC and GA SC; in 52% of simulations 
versus INFβ -1a 22 mcg SC; in 65% of simulations versus teriflunomide; and in 100% 
of simulations versus fingolimod. cOnclusiOns: In this analysis DMF showed 
dominance in ICER against IFNβ -1a IM, IFNβ -1a 44 mcg SC, IFNβ -1b SC, GA SC, 
teriflunomide and fingolimod.
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Objectives: Congenital Adrenal Hyperplasia (CAH) is one of the core conditions 
for which all states plus D.C. require newborn screening. Yoo and Grosse (2009) 
(Y/G) performed a CEA using a national incidence figure, indicating a lack of cost-
effectiveness for CAH screening (ICER, $292,000/life year gained). However, the 
incidence of the disease varies among the states, which could affect the cost-
effectiveness of the screening. Here we examine variability in that ICER due to 
variation in state incidence. MethOds: We reconstructed a decision tree from Y/G 
to reproduce their deterministic ICER for CAH screening. We then ran the model 
for every state having a record of cases of CAH in the last year we were able to find 
incidence measures for most states (2006) to estimate ICERs by state. Results: 
We were able to approximately reproduce the Y/G result for the ICER ( $293,927 
per life year saved vs. $ 292,000 from Y/G, difference < 1%). After excluding states 
with missing data (5) and states with zero measured 2006 incidence (13), the ICERs 
of the remaining 33 states are shown, as expected, to inversely relate to the state 
incidence. The ICERs ranged from $37,535 (D.C.) to $1,514,018 (Illinois) per life year 
saved (median, $303,555). Three of the 33 states have ICERs less than $150,000 per 
life year. cOnclusiOns: Different incidences of CAH have a clear effect on the 
Y/G ICERs of CAH newborn screening. In contrast to the general results from Y/G, 
using a national average incidence, 3 states have ICERs in a range that indicates 
possible cost-effectiveness in a deterministic model (ICER < $ 150,000), suggest-
ing that a PSA may be an interesting extension to assess the level of uncertainty 
around the state-level ICER estimates.
Pack-size data were sourced from the NHSBA December 2014 Drug Tariff and BNF 
68. A ‘comparable’ drug had the same active ingredient, concentration and admin-
istration method as the prescribed drug. Cost-savings, had the cheapest compa-
rable drugs been prescribed, were calculated as: [total NIC in 2014] – ([total mg of 
prescribed drugs] x [£/mg of cheapest comparable drugs]). The branded cost range, 
had only branded prescribing occurred, was calculated as: [total mg of prescribed 
drugs] x [£/mg of the most or least expensive branded comparable drugs]. Results: 
Actual total NIC for antiepileptics in 2014 was £498,552,273. Had the cheapest com-
parable drug always been prescribed, this would have decreased by £95,853,020. 
The greatest cost-savings would have been in MHRA categories 2 (40%) and 3 (44%). 
Had branded prescribing always occurred, total NIC would have increased between 
£58,988,547 (if cheapest branded drug prescribed) and £86,315,621 (if most expensive 
branded drug prescribed). The greatest increase would have been in MHRA category 
2 (£34,267,393 to £44,191,174). cOnclusiOns: It was estimated that greater branded 
prescribing of antiepileptics would have increased total NIC by between 12% and 
17%. Only prescribing generically could have decreased total NIC by 19%. These 
estimates should be considered in light of increased risk for, and associated cost 
of, therapeutic failure.
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Objectives: To describe relationships among persistency with subcutaneous inter-
feron beta-1a (scIFNβ 1a), relapse timing relative to discontinuation, and medical 
costs in patients with multiple sclerosis (MS). MethOds: Patients (aged 18-63 years) 
with ≥ 1 MS claim (ICD-9-CM:340.xx) and an initial scIFNβ 1a claim (index event), 12 
months of continuous eligibility before and 24 months after index were identified 
in the IMS PharMetrics Plus™ database. Discontinuation was defined as a ≥ 90 day 
gap in scIFNβ 1a therapy. Relapse was defined as the first post-index MS-related 
inpatient stay, emergency room (ER) visit or MS outpatient visit with a corticosteroid 
claim ±7 days. Relapse was categorized as before or after scIFNβ 1a discontinuation. 
Medical costs [excluding disease-modifying drug (DMD) costs] per day (US$) pre or 
post discontinuation of scIFNβ 1a are presented. Costs were evaluated with general-
ized linear regression models using gap, time of first relapse and the interaction 
as predictors. Prior costs, age, gender and time until relapse were evaluated as 
covariates. Results: 1540 MS patients met the study criteria; 29.2% had a relapse 
and 50% (n= 770) discontinued scIFNβ 1a during the follow-up period. Patients dis-
continuing scIFNβ 1a averaged 250 (SD= 182) days of treatment and 33.1% relapsed, 
while those who did not discontinue averaged 726 (SD= 15) days of treatment and 
25.2% relapsed (p< 0.01). Non-DMD medical cost/day was lowest for patients with no 
gap and no relapse ($24.71/day). Patients who discontinued scIFNβ 1a and had their 
first relapse after discontinuation, had non-DMD medical costs of $39.04/day prior 
to discontinuation, and $52.29/day after discontinuation. Patients with no gap and a 
relapse while scIFNβ 1a was available had lower non-DMD medical costs ($38.88/day), 
than patients with a gap in scIFNβ 1a that experienced a relapse while on treatment 
($72.37/day). Models suggest that costs differ depending on gap status and timing 
of the relapse relative to scIFNβ 1a discontinuation (p< 0.01). cOnclusiOns: These 
results suggest the value of maintaining scIFNβ 1a treatment.
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Objectives: To analyze factors of recent evolution of Multiple Sclerosis 
(MS) Disease Modifying Therapies (DMT) budgets in Spain between 2004 and 
2014. MethOds: 2004-2014 single DMT monthly expenditure was provided by IMS 
Health. For each DMT line: (First line: subcutaneous and intramuscular interferon 
(IFN) β -1a, subcutaneous IFN β -1b and glatiramer acetate injection. Second line: 
natalizumab and fingolimod) were calculated monthly and annually evolution of 
number of patients, billing, drug cost per patient and cost per year of treatment. 
Two periods: 2004-2014 and 2007 (start marketing second lines DMT)-2014 period 
were analyzed for each DMT line. Results: During 2004-2014 DMT expenditure 
increased from 115.5M€ to 353.8M€ due to: A greater number of patients 165% 
(10.27% annual growth per year) and a further growth of annual cost per patient: 
15.82% (1.48 % annual growth per year). In December 2014 second lines correspond 
to a 35.63% of DMT expenditure. Annual cost per patient in second line represents 
53% over cost per treated patient and 82% greater than first line DMT cost per 
year. If year 2007 is omitted from analysis (Only 68 second-line treatments and 
1.44M€ of associated expense) and is analyzed 2008-2014 period, second-line DMT 
represent 61% of new treatments causing a 78% increase in DMT expenditure. In 
2014 second line DMT participation reaches 86% of new regimens causing the 
91.23% of increase DMT expenditure. cOnclusiOns: The growing incorporation 
of new therapies and the appreciable rise in the number of treated patients (10.27 
% annual growth per year) are components to consider in the pharmaceutical 
budget management.
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